Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 10/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 8/20 | 0.33 |
| ▸ | PDE4A | P27815 | 6/20 | 0.33 |
| ▸ | PDE4C | Q08493 | 6/20 | 0.33 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.32 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.30 |
| ▸ | IDH1 | O75874 | 3/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2908517 | 1.00 | PDE4D (0.33) | PDE4DPDE4BPDE4APDE4CMAP4K4 | |
| SCHEMBL2908809 | 0.80 | PDE4D (0.33) | PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL2909161 | 0.80 | PDE4D (0.33) | PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL2902820 | 0.69 | KMT2A (0.34) | PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL2908814 | 0.69 | KMT2A (0.34) | PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL2901991 | 0.69 | PDE4D (0.37) | PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL2906081 | 0.69 | PDE4D (0.37) | PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL2908191 | 0.67 | PDE4D (0.37) | PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL2909252 | 0.67 | PDE4D (0.37) | PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL2910476 | 0.65 | ADORA2A (0.36) | PDE4DPDE4BPDE4APDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1692109-B1 | PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING N-SUBSTITUTED DIARYLAMINE ANALOGS | MEMORY PHARM CORP (US) | 2010-08-18 | — | — | EP | claimed |
| US-20050222207-A1 | Phosphodiesterase 4 inhibitors, including N-substituted diarylamine analogs | MEMORY PHARMACEUTICAL CORPORATION | 2005-10-06 | — | — | US | claimed |
| EP-1692109-B1 | PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING N-SUBSTITUTED DIARYLAMINE ANALOGS | MEMORY PHARM CORP (US) | 2010-08-18 | — | — | EP | disclosed |
| US-20050222207-A1 | Phosphodiesterase 4 inhibitors, including N-substituted diarylamine analogs | MEMORY PHARMACEUTICAL CORPORATION | 2005-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222207-A1 | Phosphodiesterase 4 inhibitors, including N-substituted diarylamine analogs | PDE4A, PDE4B, PDE3B | PDE4D 6/4885PDE4B 2/4885PDE4A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.